

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:**V11X** • T12G • I13L • K14V • **I15N** • **G16S** • G17R • **Q18T** • **L19A** • E35D • M36I • R41K • R57K • H69K • L89M

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:None

RT Other Mutations:K11T • K20R • V35T • T39E • K122E • D123G • K173L • Q174K • D177E • V179I • T200A • I202V • Q207D • **Δ210** • **R211*** • **W212V** • **Δ220** • **H221X** • Q222H • K223Q • E224K • P225T • P226S • E233D • **L234S** • **H235S** • **P236D** • D237N • **K238D** • **W239S** • **T240Q** • V241L • **Q242Y** • P243T • **I244A** • V245D • L246R • P247Q • **E248L** • **K249T** • **D250V** • **S251M** • **L260X** • V261I • **G262Q** • K263N • **L264*** • **N265W** • **W266K** • **A267L** • **S268M** • **Q269A** • I270V • **Y271N** • **A272L** • **G273C** • **I274R** • **K275*** • K277N • **Q278T** • **K281N** • **L282S** • L283F • **G285E**

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

Other

- V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.
- P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility. **P225T** is a highly unusual mutation at this position.
- L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been well characterized. **L234S** is a highly unusual mutation at this position.
- P236L is a rare mutation selected commonly by DLV, which appears to have little if any effect on current NNRTIs. **P236D** is a highly unusual mutation at this position.
- K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility. **K238D** is a highly unusual mutation at this position.

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.